Search clinical trials for: Obinutuzumab

Total 269 results

BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, New Zealand, United States, Canada
Incyte Corporation

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Lymphoma

Spain, Hungary, United States, Denmark, Italy, Czechia
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
Genentech, Inc.

Completed

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
University of California, San Diego
Genentech, Inc.; Celgene Corporation

Withdrawn

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Chronic Lymphocytic Leukemia

United States
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

B-Cell Chronic Lymphocytic Leukemia

Italy, Spain, Israel, United Kingdom, Latvia
King Faisal Specialist Hospital & Research Center

Unknown

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Saudi Arabia
AbbVie

Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Gilead Sciences

Active, not recruiting

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

B-cell Malignancies

United States, United Kingdom, France
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, France, Spain, Poland, United Kingdom, Australia, Belgium, Canada
Hoffmann-La Roche
AbbVie; German CLL Study Group

Active, not recruiting

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Spain, France, United Kingdom, Australia, Canada, Denmark, Germany, Italy, Brazil, Argentina, Estonia, New Zealand, Austria, Bulgaria, Croatia, Romania, Russian Federation, Poland, Switzerland, Mexico
German CLL Study Group
Gilead Sciences; Hoffmann-La Roche

Completed

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Chronic Lymphocytic Leucemia

Germany
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Providence Health & Services

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

France, United States
Weill Medical College of Cornell University
NeoTX Therapeutics Ltd.

Withdrawn

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Urothelial Carcinoma

United States
German CLL Study Group
AstraZeneca

Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Chronic Lymphocytic Leukemia

Germany
Peter MacCallum Cancer Centre, Australia

Recruiting

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE)

Follicular Lymphoma

United States, Australia
Genentech, Inc.

Completed

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Lymphoma, B-Cell

United States
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Hoffmann-La Roche

Active, not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

Belgium, Spain, Denmark, Italy, United Kingdom, Israel, United States
Emory University
National Cancer Institute (NCI); Genentech, Inc.; National Institutes of Health...

Active, not recruiting

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | t(11;14) Positive

United States
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
Hoffmann-La Roche

Completed

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States, Spain, United Kingdom
Aptevo Therapeutics

Terminated

Phase 1b Safety and Efficacy Study of TRU-016

Chronic Lymphocytic Leukemia | Peripheral T-cell Lymphoma

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more
The Lymphoma Academic Research Organisation
Hoffmann-La Roche

Terminated

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (GAINED)

Diffuse Large B Cell Lymphoma CD20 Positive

France, Belgium
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
Alexey Danilov, MD
Gilead Sciences; Oregon Health and Science University

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Anemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditions

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Completed

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Genentech, Inc.; Oregon Health and Science University

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Central Nervous System B-Cell Non-Hodgkin Lymphoma

United States
University of California, San Diego

Completed

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

CLL | Richter's Syndrome

United States
Medical Practice Prof D. Ivanov

Enrolling by invitation

The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) (IMPULsKF)

Gout | CKD Stage 1-4 | SUA Level (>8 mg/dL; 480 µmol/L)

Ukraine
PrECOG, LLC.
Genentech, Inc.

Terminated

Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (PrE0401)

Indolent Non-Hodgkin's Lymphoma

United States
Hoffmann-La Roche

Recruiting

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Non-Hodgkin Lymphoma | B-Cell Lymphoma

Italy, France, Australia, United States, Canada, Denmark, United Kingdom, Spain, Germany
French Innovative Leukemia Organisation
Roche Pharma AG; Janssen-Cilag Ltd.

Completed

Phase II Trial GA101 Inbrutinib B CLL (ICLL07GAI)

Leukemia, Lymphocytic, Chronic, B-Cell

France
Mỹ Đức Hospital

Completed

Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

Poor Ovarian Response

Vietnam
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

China
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Syndax Pharmaceuticals

Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer

Ireland, United Kingdom
Genentech, Inc.

Completed

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Lymphocytic Leukemia, Chronic

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Hoffmann-La Roche

Completed

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Italy, Sweden, Belgium, Brazil, Canada, Germany, Ireland, Korea, Republic of, Spain, Russian Federation, France, Finland, Israel, Estonia, Romania, Egypt, Thailand, Switzerland, Bosnia and Herzegovina, Slovakia, Turkey, Lithuania, P... and more
Christine Ryan
Genentech, Inc.

Recruiting

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Chronic Lymphocytic Leukemia | Richter's Transformation

United States
NeoTX Therapeutics Ltd.
Translational Drug Development

Completed

Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1)

Non-small Cell Lung Cancer

United States
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, France, Germany
Hoffmann-La Roche

Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO)

Mature B-Cell Non-Hodgkin Lymphoma

United States, Spain, Korea, Republic of, France, Denmark, Australia, Germany, Italy

Search clinical trials for: Obinutuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations